Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 527Brain Neoplasms 415Glioma 343Astrocytoma 239Central Nervous System Neoplasms 201Neuroblastoma 195Gliosarcoma 163Oligodendroglioma 149Medulloblastoma 118Neoplasms 113Ependymoma 72Recurrence 70Breast Neoplasms 69Sarcoma 65Melanoma 62Carcinoma, Non-Small-Cell Lung 58Osteosarcoma 57Diffuse Intrinsic Pontine Glioma 48Wilms Tumor 47Familial ependymoma 47Lymphoma 46Neoplasm Metastasis 45Optic Nerve Glioma 44Rhabdomyosarcoma 42Rhabdoid Tumor 42Lung Neoplasms 42Choroid Plexus Neoplasms 42Neuroectodermal Tumors, Primitive 38Meningeal Carcinomatosis 38Ovarian Neoplasms 37

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Xeroderma Pigmentosum × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡